201 related articles for article (PubMed ID: 38178784)
1. Antibodies to watch in 2024.
Crescioli S; Kaplon H; Chenoweth A; Wang L; Visweswaraiah J; Reichert JM
MAbs; 2024; 16(1):2297450. PubMed ID: 38178784
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to watch in 2023.
Kaplon H; Crescioli S; Chenoweth A; Visweswaraiah J; Reichert JM
MAbs; 2023; 15(1):2153410. PubMed ID: 36472472
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to watch in 2019.
Kaplon H; Reichert JM
MAbs; 2019; 11(2):219-238. PubMed ID: 30516432
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to watch in 2020.
Kaplon H; Muralidharan M; Schneider Z; Reichert JM
MAbs; 2020; 12(1):1703531. PubMed ID: 31847708
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to watch in 2021.
Kaplon H; Reichert JM
MAbs; 2021; 13(1):1860476. PubMed ID: 33459118
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to watch in 2022.
Kaplon H; Chenoweth A; Crescioli S; Reichert JM
MAbs; 2022; 14(1):2014296. PubMed ID: 35030985
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to watch in 2018.
Kaplon H; Reichert JM
MAbs; 2018; 10(2):183-203. PubMed ID: 29300693
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to watch in 2017.
Reichert JM
MAbs; 2017; 9(2):167-181. PubMed ID: 27960628
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to watch in 2015.
Reichert JM
MAbs; 2015; 7(1):1-8. PubMed ID: 25484055
[TBL] [Abstract][Full Text] [Related]
10. Antibodies to watch in 2016.
Reichert JM
MAbs; 2016; 8(2):197-204. PubMed ID: 26651519
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates: present and future.
Beck A; Reichert JM
MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to watch in 2014.
Reichert JM
MAbs; 2014 Jan; 6(1):5-14. PubMed ID: 24284914
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab Deruxtecan: First Approval.
Keam SJ
Drugs; 2020 Apr; 80(5):501-508. PubMed ID: 32144719
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to watch in 2014: mid-year update.
Reichert JM
MAbs; 2014; 6(4):799-802. PubMed ID: 24846335
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer.
Andrikopoulou A; Zografos E; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Clin Breast Cancer; 2021 Jun; 21(3):e212-e219. PubMed ID: 32917537
[TBL] [Abstract][Full Text] [Related]
16. 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
Beck A; Wurch T; Reichert JM
MAbs; 2011; 3(2):111-32. PubMed ID: 21441785
[TBL] [Abstract][Full Text] [Related]
17. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
18. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to watch in 2013: Mid-year update.
Reichert JM
MAbs; 2013; 5(4):513-7. PubMed ID: 23727858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
